# Compare Neoadjuvant Chemotherapy of DOS Versus SOX in Locally Advanced Gastric Adenocarcinoma.

> **NCT03691454** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Peking University** · enrollment: 258 (estimated)

## Conditions studied

- Gastric Adenocarcinoma

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT03691454
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-06-28
- **Primary completion:** 2022-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 258 (ESTIMATED)
- **Last updated:** 2018-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03691454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03691454, "Compare Neoadjuvant Chemotherapy of DOS Versus SOX in Locally Advanced Gastric Adenocarcinoma.". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT03691454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*